Kidney Cancer Outcomes at KFSYSCC

Between 2015-2019, the five-year survival rate for kidney cancer at KFSYSCC was 75.1%.

Basic Information and Stage Distribution of 526 Kidney Cancer Patients at KFSYSCC from 1990-2019

  
    


    
    
    


    
    
        
                
                Total
                1990-1994
                1995-1999
                2000-2004
                2005-2009
                2010-2014
                2015-2019
            

        
                n
                526
                10 (2%)
                45 (9%)
                121 (23%)
                116 (22%)
                123 (23%)
                111 (21%)
            

                Gender (%)
            

                Male
                338 (64%)
                7 (70%)
                26 (58%)
                73 (60%)
                75 (65%)
                83 (67%)
                74 (67%)
            

                Female
                188 (36%)
                3 (30%)
                19 (42%)
                48 (40%)
                41 (35%)
                40 (33%)
                37 (33%)
            

                Age
            

                Mean/Median
                58/59
                60/64
                59/62
                58/61
                59/58
                55/56
                58/59
            

                Range
                3-91
                35-72
                32-87
                3-88
                14-89
                16-91
                20-86
            

                Q1-Q3
                48-68
                53-70
                50-67
                48-70
                48-71
                46-64
                49-68
            

                Stage (%)
            

                0
                1 (0.2%)
                0 (0%)
                0 (0%)
                1 (1%)
                0 (0%)
                0 (0%)
                0 (0%)
            

                I
                209 (40%)
                2 (20%)
                7 (16%)
                34 (28%)
                50 (43%)
                57 (46%)
                59 (53%)
            

                II
                37 (7%)
                1 (10%)
                4 (9%)
                12 (10%)
                9 (8%)
                7 (6%)
                4 (4%)
            

                III
                106 (20%)
                1 (10%)
                4 (9%)
                12 (10%)
                29 (25%)
                37 (30%)
                23 (21%)
            

                IV
                102 (19%)
                2 (20%)
                12 (27%)
                27 (22%)
                19 (16%)
                19 (15%)
                23 (21%)
            

                Unknown
                71 (14%)
                4 (40%)
                18 (40%)
                35 (29%)
                9 (8%)
                3 (2%)
                2 (2%)
            

    




  

	Total	1990-1994	1995-1999	2000-2004	2005-2009	2010-2014	2015-2019
n	526	10 (2%)	45 (9%)	121 (23%)	116 (22%)	123 (23%)	111 (21%)
Gender (%)
Male	338 (64%)	7 (70%)	26 (58%)	73 (60%)	75 (65%)	83 (67%)	74 (67%)
Female	188 (36%)	3 (30%)	19 (42%)	48 (40%)	41 (35%)	40 (33%)	37 (33%)
Age
Mean/Median	58/59	60/64	59/62	58/61	59/58	55/56	58/59
Range	3-91	35-72	32-87	3-88	14-89	16-91	20-86
Q1-Q3	48-68	53-70	50-67	48-70	48-71	46-64	49-68
Stage (%)
0	1 (0.2%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
I	209 (40%)	2 (20%)	7 (16%)	34 (28%)	50 (43%)	57 (46%)	59 (53%)
II	37 (7%)	1 (10%)	4 (9%)	12 (10%)	9 (8%)	7 (6%)	4 (4%)
III	106 (20%)	1 (10%)	4 (9%)	12 (10%)	29 (25%)	37 (30%)	23 (21%)
IV	102 (19%)	2 (20%)	12 (27%)	27 (22%)	19 (16%)	19 (15%)	23 (21%)
Unknown	71 (14%)	4 (40%)	18 (40%)	35 (29%)	9 (8%)	3 (2%)	2 (2%)

Based on KFSYSCC's cancer registry from 1990 to 2019, there were 526 analytic kidney cancer cases, with 338 males (64%) and 188 females (36%). The average and median ages were 58 and 59 years old, respectively; the youngest patient was 3 years old, and the oldest was 91 years old; the interquartile range (Q1-Q3) was 48-68. By stage, there were 1 stage 0 kidney cancer patients (0.2%), 209 stage I patients (40%), 37 stage II patients (7%), 106 stage III patients (20%), and 102 stage IV patients (19% The basic information and stage distribution of all kidney cancer patients, sorted by the year of diagnosis, are presented in the table above.

Distorted and corrupted graph with multiple colored lines and bars, making it unreadable and unclear.

Survival Curves for 526 Kidney Cancer Patients (1990-2019), Stratified by Year of Diagnosis

From 1990 to 2019, the chart illustrates the five-year observed survival rates for 526 kidney cancer patients at KFSYSCC, stratified by the year of diagnosis. The graph shows the five-year survival rate for kidney cancer increased from 40% in 1990-1994 to 75% in 2015-2019, while the ten-year survival rate rose from 20% in 1990-1994 to 72% in 2010-2014.

Treatment Methods and Stages for 111 Kidney Cancer Patients at KFSYSCC (2015-2019)

  
    


    
    
    


    
    
        
            Category
            Total
            Stage I
            Stage II
            Stage III
            Stage IV
            Unknown
        

            Total
            111
            59
            4
            23
            23
            2
        

            Surgical Treatment
            96 (86%)
            59 (100%)
            4 (100%)
            21 (91%)
            10 (43%)
            2 (100%)
        

            Radiation Therapy
            10 (9%)
            0 (0%)
            0 (0%)
            1 (4%)
            9 (39%)
            0 (0%)
        

            Chemotherapy
            5 (5%)
            0 (0%)
            0 (0%)
            2 (9%)
            3 (13%)
            0 (0%)
        

            Targeted Therapy
            14 (13%)
            0 (0%)
            0 (0%)
            1 (4%)
            13 (57%)
            0 (0%)
        

            Hormone Therapy
            0 (0%)
            -
        

            Immunotherapy
            2 (2%)
            0 (0%)
            0 (0%)
            0 (0%)
            2 (9%)
            0 (0%)
        

            Palliative Care
            8 (7%)
            0 (0%)
            0 (0%)
            1 (4%)
            7 (30%)
            0 (0%)
        

            Bone Marrow/Stem Cell Transplant
            0 (0%)
            -
        

            No Record of Initial Treatment Reported
            0 (0%)
            -
        





  

Category	Total	Stage I	Stage II	Stage III	Stage IV	Unknown
Total	111	59	4	23	23	2
Surgical Treatment	96 (86%)	59 (100%)	4 (100%)	21 (91%)	10 (43%)	2 (100%)
Radiation Therapy	10 (9%)	0 (0%)	0 (0%)	1 (4%)	9 (39%)	0 (0%)
Chemotherapy	5 (5%)	0 (0%)	0 (0%)	2 (9%)	3 (13%)	0 (0%)
Targeted Therapy	14 (13%)	0 (0%)	0 (0%)	1 (4%)	13 (57%)	0 (0%)
Hormone Therapy	0 (0%)	-
Immunotherapy	2 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (9%)	0 (0%)
Palliative Care	8 (7%)	0 (0%)	0 (0%)	1 (4%)	7 (30%)	0 (0%)
Bone Marrow/Stem Cell Transplant	0 (0%)	-
No Record of Initial Treatment Reported	0 (0%)	-

Between 2015 and 2019, there were a total of 111 analytic kidney cancer cases, including 59 patients in stage I, 4 in stage II, 23 in stage III, and 23 in stage IV. In terms of treatment methods, 96 patients (86%) underwent surgical treatment, 10 (9%) received radiation therapy, 5 (5%) underwent chemotherapy, 14 (13%) received targeted therapy, 2 (2%) received immunotherapy, and 8 (7%) underwent palliative care.

Graph showing the probability of ignition of different materials versus specific energy, with materials such as polyester, cotton, wool, linen, polypropylene, and acrylic.

Five-Year Survival Rates of 111 Kidney Cancer Patients by Stage (2015-2019)

KFSYSCC’s 2015-2019 five-year observed survival rates for 111 kidney cancer patients, stratified by stage, are presented in the following chart. As shown in the graph, the five-year survival rate is 96% for stage 1, 100% for stage 2, 81% for stage 3, and 13% for stage 4.